- Home
- TERN
as 12-17-2024 4:00pm EST
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 499.4M | IPO Year: | 2021 |
| Target Price: | $18.30 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.32 - $11.40 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Terns Pharmaceuticals Inc. News
TERN Breaking Stock News: Dive into TERN Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Simply Wall St.
7 days ago
Terns Pharmaceuticals CEO & Director Acquires 423% More Stock
MT Newswires
14 days ago
Oppenheimer Adjusts Price Target on Terns Pharmaceuticals to $20 From $17, Keeps Outperform Rating
GlobeNewswire
15 days ago
Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia
GlobeNewswire
16 days ago
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire
a month ago
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
Simply Wall St.
a month ago
We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth
GlobeNewswire
a month ago
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates
Compare TERN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TERN Terns Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.